METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma

By Ting Li, Pei-shan Hu, Zhixiang Zuo, Jin-Fei Lin, Xingyang Li, Qi-Nian Wu, Zhan-hong Chen, Z. Zeng, Feng Wang, Jian Zheng and 7 more. Molecular Cancer, 2019

678 citations recorded by the source corpus.

Colorectal carcinoma (CRC) is one of the most common malignant tumors, and its main cause of death is tumor metastasis. RNA N6-methyladenosine (m6A) is an emerging regulatory mechanism for gene expression and methyltransferase-like 3 (METTL3) participates in tumor progression in several cancer types. However, its role in CRC remains unexplored. Western blot, quantitative real-time PCR (RT-qPCR) and immunohistochemical (IHC) were used to detect METTL3 expression in cell lines and patient tissues. Methylated RNA immunoprecipitation sequencing (MeRIP-seq) and transcriptomic RNA sequencing (RNA-seq) were used to screen the target genes of METTL3. The biological functions of METTL3 were investigated in vitro and in vivo. RNA pull-down and RNA immunoprecipitation assays were conducted to explore the specific binding of target genes. RNA stability assay was used to detect the half-lives of the downstream genes of METTL3. Using TCGA database, higher METTL3 expression was found in CRC metastatic tissues and was associated with a poor prognosis. MeRIP-seq revealed that SRY (sex determining region Y)-box 2 (SOX2) was the downstream gene of METTL3. METTL3 knockdown in CRC cells drastically inhibited cell self-renewal, stem cell frequency and migration in vitro and suppressed CRC tumorigenesis and metastasis in both cell-based models and PDX models. Mechanistically, methylated SOX2 transcripts, specifically the coding sequence (CDS) regions, were subsequently recognized by the specific m6A “reader”, insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2), to prevent SOX2 mRNA degradation. Further, SOX2 expression positively correlated with METTL3 and IGF2BP2 in CRC tissues. The combined IHC panel, including “writer”, “reader”, and “target”, exhibited a better prognostic value for CRC patients than any of these components individually. Overall, our study revealed that METTL3, acting as an oncogene, maintained SOX2 expression through an m6A-IGF2BP2-dependent mechanism in CRC cells, and indicated a potential biomarker panel for prognostic prediction in CRC.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/723825b8701a646d93d0f55c1a0488bb85331200

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

The role of m6A RNA methylation in cancer metabolism (2022, background): “Studies have found that METTL3 plays a role of proto-oncogene in colorectal cancer, promotes the methylation level of Sox2 in a m6A dependent manner, prevents Sox2 degradation through the synergistic effect of IGF2BP2, and maintains the expression of Sox2, thus promoting the progression of colorecta”
Critical Roles of N6-Methyladenosine (m6A) in Cancer and Virus Infection (2020, background): “A global increase in m6A levels induced by METTL3 enhanced degradation of mRNAs, including NANOG, SRY-box transcription factor 2 (SOX2), Kruppel like factor 4 (KLF4), and MYC [77].”
Functions of N6-methyladenosine and its role in cancer (2019, background): “and prevents it degradation, contributing to colorectal cancer pathogenesis and progression [80].”
The potential role of RNA N6-methyladenosine in Cancer progression (2020, background): “Collectively, these findings indicate that METTL3, acting as an oncogene, relies on IGF2BP2 to inhibit SOX2 degradation, thus increasing SOX2 expression [120].”